Meglumine antimoniate

Generic Name: Meglumine antimoniate

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₈NO_₈Sb

CAS Number: 133-51-7

Unique Ingredient Identifier: 75G4TW236W

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World

Phase 3

Active, not recruiting

Conditions: Cutaneous Leishmaniases

Interventions: Drug: Meglumine Antimoniate
Drug: Miltefosine
Device: Thermotherapy machine

First Posted Date: 2020-08-17

Last Posted Date: 2024-02-22

Lead Sponsor: Drugs for Neglected Diseases

Target Recruit Count: 184

Registration Number: NCT04515186

Locations: 🇧🇷
Julio Muller University Hospital Federal University of Mato Grosso, Cuiaba, Brazil
🇧🇷
Federal University of Bahia Immunology Department, Salvador, Brazil
🇵🇪
Universidad Peruana Cayetano Heredia, Lima, Peru

and more 3 locations

Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)

Phase 3

Completed

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: Meglumine antimoniate

First Posted Date: 2020-04-09

Last Posted Date: 2020-04-09

Lead Sponsor: Tehran University of Medical Sciences

Registration Number: NCT04340128

Locations: 🇮🇷
CRTSDL, Tehran, Iran, Islamic Republic of

Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis

Phase 2

Completed

Conditions: Leishmaniasis; American
Leishmaniasis
Leishmaniasis, Cutaneous

Interventions: Drug: Immucillin DI4G
Drug: Meglumine antimoniate

First Posted Date: 2017-09-26

Last Posted Date: 2017-09-26

Lead Sponsor: Hospital Universitário Professor Edgard Santos

Target Recruit Count: 50

Registration Number: NCT03294161

Locations: 🇧🇷
Corte de Pedra Health Post, Corte de Pedra, Bahia, Brazil

Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients

Phase 2

Conditions: Drug Side Effect
Leishmaniasis; American, Cutaneous

Interventions: Drug: 18-Methoxycoronaridine
Drug: Glucantime

First Posted Date: 2017-03-21

Last Posted Date: 2020-03-19

Lead Sponsor: Infan Industria Quimica Farmaceutica Nacional

Target Recruit Count: 52

Registration Number: NCT03084952

The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil

Phase 2

Active, not recruiting

Conditions: Leishmaniasis

Interventions: Drug: Meglumine antimoniate
Drug: Miltefosine
Drug: Pentoxifylline

First Posted Date: 2015-08-21

Last Posted Date: 2024-01-16

Lead Sponsor: University of Brasilia

Target Recruit Count: 160

Registration Number: NCT02530697

Locations: 🇧🇷
Hospital Universitário de Brasília, Brasília, DF, Brazil

High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus

Phase 3

Terminated

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: Fluconazole
Drug: Meglumine Antimoniate

First Posted Date: 2013-10-01

Last Posted Date: 2015-12-02

Lead Sponsor: Hospital Universitário Professor Edgard Santos

Target Recruit Count: 53

Registration Number: NCT01953744

Locations: 🇧🇷
Posto de Saúde de Corte de Pedra, Presidente Tancredo Neves, Bahia, Brazil

Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis

Phase 2

Completed

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: Meglumine antimonate
Drug: Placebo
Drug: Pentoxifylline

First Posted Date: 2011-11-03

Last Posted Date: 2016-08-23

Lead Sponsor: Centro Internacional de Entrenamiento e Investigaciones Médicas

Target Recruit Count: 75

Registration Number: NCT01464242

Locations: 🇨🇴
Corporación Centro Internacional de entrenamiento e Investigaciónes Médicas, Cali, Valle, Colombia

Low Antimonial Dosage in American Mucosal Leishmaniasis

Phase 2

Conditions: Mucosal Leishmaniasis
Mucocutaneous Leishmaniasis

Interventions: Drug: Meglumine antimoniate

First Posted Date: 2011-02-23

Last Posted Date: 2018-07-12

Lead Sponsor: Oswaldo Cruz Foundation

Target Recruit Count: 76

Registration Number: NCT01301937

Locations: 🇧🇷
Oswaldo Cruz Foundation - IPEC/FIOCRUZ, Rio de Janeiro, Brazil

Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis

Phase 2

Completed

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: Meglumine antimoniate

First Posted Date: 2011-02-23

Last Posted Date: 2018-05-15

Lead Sponsor: Oswaldo Cruz Foundation

Target Recruit Count: 72

Registration Number: NCT01301924

Locations: 🇧🇷
Oswaldo Cruz Foundation - IPEC/FIOCRUZ, Rio de Janeiro, Brazil

Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children

Phase 4

Completed

Conditions: Visceral Leishmaniasis

Interventions: Drug: Amphotericin B-deoxycholate
Drug: Meglumine antimoniate

First Posted Date: 2009-12-15

Last Posted Date: 2017-09-05

Lead Sponsor: University of Brasilia

Target Recruit Count: 101

Registration Number: NCT01032187

Locations: 🇧🇷
Hospital de Doenças Tropicais, Araguaína, Tocantins, Brazil
🇧🇷
Hospital Dona Regina, Palmas, Tocantins, Brazil

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy